Brief: Poseida Therapeutics Announces Strategic Global Collaboration With Roche Focused On Allogeneic Car-T Cell Therapies For Hematologic Malignancies

Poseida Therapeutics

03/08/2022 13:11

Aug 3 (Reuters) - Poseida Therapeutics Inc  PSTX.O :
    * POSEIDA THERAPEUTICS ANNOUNCES STRATEGIC GLOBAL
COLLABORATION
WITH ROCHE FOCUSED ON ALLOGENEIC CAR-T CELL THERAPIES FOR
HEMATOLOGIC MALIGNANCIES
    * POSEIDA THERAPEUTICS INC - POSEIDA WILL RECEIVE $110
MILLION
UPFRONT
    * POSEIDA THERAPEUTICS INC - POSEIDA COULD RECEIVE UP TO
$110
MILLION IN NEAR-TERM MILESTONES AND OTHER PAYMENTS
    * POSEIDA THERAPEUTICS INC - POSEIDA ELIGIBLE FOR FUTURE
DEVELOPMENT AND COMMERCIAL MILESTONES AND TIERED ROYALTY
PAYMENTS
    * POSEIDA THERAPEUTICS - ROCHE TO RECEIVE EITHER EXCLUSIVE
RIGHTS
OR OPTIONS TO DEVELOP AND COMMERCIALIZE A NUMBER OF ALLOGENEIC
CAR-T PROGRAMS
    * POSEIDA THERAPEUTICS - COS TO COLLABORATE IN RESEARCH
PROGRAM TO
CREATE & DEVELOP NEXT-GENERATION FEATURES, IMPROVEMENTS FOR
ALLOGENEIC CAR-T THERAPIES
    * POSEIDA THERAPEUTICS INC - POSEIDA WILL CONDUCT PHASE 1
STUDIES
AND MANUFACTURE CLINICAL MATERIALS BEFORE TRANSITIONING PROGRAMS
TO ROCHE
    * POSEIDA THERAPEUTICS - ROCHE TO BE SOLELY RESPONSIBLE FOR
LATE-STAGE DEVELOPMENT, GLOBAL COMMERCIALIZATION OF ALL PRODUCTS
UNDER AGREEMENT
    * POSEIDA THERAPEUTICS - CO ELIGIBLE TO RECEIVE RESEARCH,
DEVELOPMENT, LAUNCH, NET SALES MILESTONES, PAYMENTS POTENTIALLY
UP TO $6 BILLION IN AGGREGATE VALUE

Source text for Eikon:  ID:nPn6C8P3ma 
Further company coverage:  PSTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))